Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Stud...

por Ohta, Ken, Ichinose, Masakazu, Tohda, Yuji, Engel, Michael, Moroni-Zentgraf, Petra, Kunimitsu, Satoko, Sakamoto, Wataru, Adachi, Mitsuru
Publicado 2015